RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors

An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFirst Affiliated Hospital of Wannan Medical College皖南医科大学第一附属医院WuhuHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06126406, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Advanced, metastatic or recurrent malignant tumors diagnosed by histology or pathology, mainly colorectal cancer, esophageal cancer, gastric cancer, and pancreatic cancer;

    Inclusion criterion 2

  3. Received the following anti-tumor treatments before screening: Received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter);

    Exclusion criterion 4

    Except for alopecia or peripheral neuropathy, the toxicity of previous anti-tumor therapy has not improved to the baseline level or ≤ grade 1;

    Exclusion criterion 8

  4. ECOG score 0-2 points;

    Inclusion criterion 6

  5. Blood routine: white blood cells>3.0×10\^9/L,neutrophils>0.8×10\^9/L, lymphocytes cells>0.5×10\^9/L,platelets>75×10\^9/L, hemoglobin>80g/L;

    Inclusion criterion 9

    Renal function: serum creatinine≤2.0×ULN;

    Inclusion criterion 11

    Liver function: ALT and AST ≤3.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤5.0×ULN);

    Inclusion criterion 12

    Total bilirubin≤3.0×ULN;

    Inclusion criterion 13

  6. At least one assessable lesion according to RECIST 1.1 criteria,For extranodal lesions, the length and diameter should be ≥10mm. For nodular lesions, the short diameter of the lymph node should be ≥15mm;

    Inclusion criterion 5

  7. Suffering from other uncured malignant tumors in the past 3 years or at the same time, except cervical carcinoma in situ and basal cell carcinoma of the skin;

    Exclusion criterion 15

    Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer test is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive;

    Exclusion criterion 16

  8. Subjects agree to use reliable and effective contraceptive methods for contraception within 1 year after signing the informed consent form to receiving CAR-T cell infusion (excluding rhythm contraception);

    Inclusion criterion 16

    Women who are pregnant or breastfeeding;

    Exclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06126406, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years old, male or female;
  • Advanced, metastatic or recurrent malignant tumors diagnosed by histology or pathology, mainly colorectal cancer, esophageal cancer, gastric cancer, and pancreatic cancer;
  • After receiving at least second-line standard treatment failure (disease progression or intolerance, such as surgery, chemotherapy, radiotherapy, etc.) or lack of effective treatment methods;
  • Immunohistochemical staining of tumor samples within 3 months confirmed that the tumor was CEA positive (clear membrane staining, positive rate ≥ 10%); , the positive rate ≥ 10%), the serum CEA of the patient is required to exceed 10ug/L.
  • At least one assessable lesion according to RECIST 1.1 criteria,For extranodal lesions, the length and diameter should be ≥10mm. For nodular lesions, the short diameter of the lymph node should be ≥15mm;
  • ECOG score 0-2 points;
  • No serious mental disorder;
  • Unless otherwise specified, the function of the vital organs of the subject shall meet the following conditions:
  • Blood routine: white blood cells>3.0×10\^9/L,neutrophils>0.8×10\^9/L, lymphocytes cells>0.5×10\^9/L,platelets>75×10\^9/L, hemoglobin>80g/L;
  • Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram;
  • Renal function: serum creatinine≤2.0×ULN;
  • Liver function: ALT and AST ≤3.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤5.0×ULN);
  • Total bilirubin≤3.0×ULN;
  • Oxygen saturation ≥95% in non-oxygen state.
  • Have apheresis or venous blood collection standards, and have no other contraindications for cell collection;
  • Subjects agree to use reliable and effective contraceptive methods for contraception within 1 year after signing the informed consent form to receiving CAR-T cell infusion (excluding rhythm contraception);
  • The patients themselves or their guardians agree to participate in this clinical trial and sign the ICF, indicating that they understand the purpose and procedures of this clinical trial and are willing to participate in the research.

Exclusion Criteria:

  • Those who have central nervous system metastasis or meningeal metastasis at the time of screening are judged by the investigator to be unsuitable for inclusion;
  • Participated in other clinical studies within 1 month before screening;
  • vaccinated with live attenuated vaccine within 4 weeks before screening;
  • Received the following anti-tumor treatments before screening: Received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter);
  • Active infection or uncontrollable infection requiring systemic treatment;
  • Patients with intestinal obstruction, active gastrointestinal bleeding, or a history of gastrointestinal bleeding within 3 months;
  • There is a large amount of uncontrolled fluid accumulation in the serous cavity;
  • Except for alopecia or peripheral neuropathy, the toxicity of previous anti-tumor therapy has not improved to the baseline level or ≤ grade 1;
  • Suffering from any of the following heart diseases:
  • New York Heart Association (NYHA) stage III or IV congestive heart failure;
  • Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months before enrollment;
  • Clinically significant ventricular arrhythmia, or a history of unexplained syncope (except those caused by vasovagal or dehydration);
  • History of severe non-ischemic cardiomyopathy;
  • Patients with active autoimmune disease, or other patients requiring long-term immunosuppressive therapy;
  • Suffering from other uncured malignant tumors in the past 3 years or at the same time, except cervical carcinoma in situ and basal cell carcinoma of the skin;
  • Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer test is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive;
  • Women who are pregnant or breastfeeding;
  • Other investigators deem it unsuitable to participate in the research.

Quoted from ClinicalTrials.gov, NCT06126406, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06126406, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06126406